Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.56
UTHR's Cash to Debt is ranked higher than
62% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. UTHR: 1.56 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.69   Max: 15951.56
Current: 1.56

0.69
15951.56
Equity to Asset 0.60
UTHR's Equity to Asset is ranked higher than
69% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. UTHR: 0.60 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.97
Current: 0.6

0.37
0.97
Interest Coverage 16.20
UTHR's Interest Coverage is ranked higher than
54% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 16.20 )
UTHR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 3302.25
Current: 16.2

2.02
3302.25
F-Score: 6
Z-Score: 6.48
M-Score: -2.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.19
UTHR's Operating margin (%) is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. UTHR: 26.19 )
UTHR' s 10-Year Operating margin (%) Range
Min: -13300   Max: 46.03
Current: 26.19

-13300
46.03
Net-margin (%) 15.63
UTHR's Net-margin (%) is ranked higher than
90% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. UTHR: 15.63 )
UTHR' s 10-Year Net-margin (%) Range
Min: -12800   Max: 56.09
Current: 15.63

-12800
56.09
ROE (%) 13.86
UTHR's ROE (%) is ranked higher than
92% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. UTHR: 13.86 )
UTHR' s 10-Year ROE (%) Range
Min: -76.65   Max: 36.15
Current: 13.86

-76.65
36.15
ROA (%) 8.36
UTHR's ROA (%) is ranked higher than
92% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. UTHR: 8.36 )
UTHR' s 10-Year ROA (%) Range
Min: -68.45   Max: 22.31
Current: 8.36

-68.45
22.31
ROC (Joel Greenblatt) (%) 62.91
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. UTHR: 62.91 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1372.3   Max: 90.44
Current: 62.91

-1372.3
90.44
Revenue Growth (%) 27.40
UTHR's Revenue Growth (%) is ranked higher than
92% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. UTHR: 27.40 )
UTHR' s 10-Year Revenue Growth (%) Range
Min: 25.8   Max: 317.9
Current: 27.4

25.8
317.9
EBITDA Growth (%) 25.50
UTHR's EBITDA Growth (%) is ranked higher than
94% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. UTHR: 25.50 )
UTHR' s 10-Year EBITDA Growth (%) Range
Min: -56   Max: 127.7
Current: 25.5

-56
127.7
EPS Growth (%) 20.60
UTHR's EPS Growth (%) is ranked higher than
91% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. UTHR: 20.60 )
UTHR' s 10-Year EPS Growth (%) Range
Min: -50.4   Max: 153.6
Current: 20.6

-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

UTHR Guru Trades in Q3 2013

Joel Greenblatt 372,147 sh (+9.03%)
Vanguard Health Care Fund Sold Out
David Dreman Sold Out
John Hussman 358,000 sh (-23.5%)
Jim Simons 440,778 sh (-25.34%)
Paul Tudor Jones 7,700 sh (-50.64%)
» More
Q4 2013

UTHR Guru Trades in Q4 2013

Steven Cohen 24,174 sh (New)
Paul Tudor Jones 5,100 sh (-33.77%)
Joel Greenblatt 194,595 sh (-47.71%)
Jim Simons 224,278 sh (-49.12%)
John Hussman 134,000 sh (-62.57%)
» More
Q1 2014

UTHR Guru Trades in Q1 2014

Paul Tudor Jones 9,167 sh (+79.75%)
Joel Greenblatt 316,489 sh (+62.64%)
Jim Simons 287,940 sh (+28.39%)
John Hussman 134,000 sh (unchged)
Steven Cohen 2,497 sh (-89.67%)
» More
Q2 2014

UTHR Guru Trades in Q2 2014

Joel Greenblatt 646,066 sh (+104.14%)
John Hussman 134,000 sh (unchged)
Paul Tudor Jones 8,168 sh (-10.9%)
Jim Simons 252,478 sh (-12.32%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 104.14%0.37%$86.14 - $107.81 $ 117.8322%646066
Joel Greenblatt 2014-03-31 Add 62.64%0.17%$90.67 - $113.39 $ 117.8315%316489
John Hussman 2013-12-31 Reduce -62.57%1%$80.03 - $114.51 $ 117.8331%134000
Joel Greenblatt 2013-12-31 Reduce -47.71%0.45%$80.03 - $114.51 $ 117.8331%194595
John Hussman 2013-09-30 Reduce -23.5%0.33%$66.1 - $79.58 $ 117.8361%358000
Vanguard Health Care Fund 2013-09-30 Sold Out 0.32%$66.1 - $79.58 $ 117.8361%0
David Dreman 2013-09-30 Sold Out 0.12%$66.1 - $79.58 $ 117.8361%0
Joel Greenblatt 2013-06-30 Add 15.34%0.13%$59.64 - $69.31 $ 117.8383%341330
David Dreman 2012-12-31 New Buy0.09%$44.99 - $58.91 $ 117.83126%57025
John Hussman 2012-09-30 New Buy0.67%$49.73 - $58.2 $ 117.83118%500000
Joel Greenblatt 2012-06-30 Add 101.59%0.6%$41.19 - $49.51 $ 117.83167%332744
Richard Perry 2012-06-30 Sold Out 0.04%$41.19 - $49.51 $ 117.83167%0
Joel Greenblatt 2012-03-31 Add 82.68%0.31%$45.54 - $50.99 $ 117.83161%165063
Richard Perry 2012-03-31 New Buy0.04%$45.54 - $50.99 $ 117.83161%15300
Joel Greenblatt 2011-12-31 Add 38.75%0.15%$37.21 - $47.54 $ 117.83183%90355
Joel Greenblatt 2011-09-30 Add 274.82%0.29%$37.47 - $57.38 $ 117.83143%65122
Vanguard Health Care Fund 2011-09-30 Add 77.9%0.16%$37.47 - $57.38 $ 117.83143%1787000
Michael Price 2011-09-30 Sold Out 0.1%$37.47 - $57.38 $ 117.83143%0
George Soros 2011-09-30 Sold Out 0.0776%$37.47 - $57.38 $ 117.83143%0
Michael Price 2011-06-30 Reduce -82.59%0.59%$53.49 - $70.7 $ 117.8386%12500
Vanguard Health Care Fund 2011-06-30 Add 183.36%0.18%$53.49 - $70.7 $ 117.8386%1004500
Joel Greenblatt 2011-06-30 New Buy0.13%$53.49 - $70.7 $ 117.8386%17374
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK